



Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Original article

Prevalence of quinolone resistance mechanisms in *Enterobacteriaceae* producing acquired AmpC β-lactamases and/or carbapenemases in Spain[☆]



Jesús Machuca^{a,b,*}, Jesús Agüero^{b,c,d}, Elisenda Miró^{b,e}, María del Carmen Conejo^{b,f}, Jesús Oteo^{b,g}, Germán Bou^{b,h}, Juan José González-López^{b,i}, Antonio Oliver^{b,j}, Ferran Navarro^{b,e}, Álvaro Pascual^{a,b,f}, Luis Martínez-Martínez^{b,c,d}

^a Unidad Clínica Intercentros de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Rocío, Sevilla, Spain

^b Red Española de Investigación en Patología Infecciosa (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain

^c Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain

^d Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain

^e Servicio de Microbiología, Hospital de la Santa Creu i Sant Pau-Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain

^f Departamento de Microbiología, Universidad de Sevilla, Sevilla, Spain

^g Laboratorio de Referencia e Investigación en Resistencia a Antibióticos e Infecciones Relacionadas con la Asistencia Sanitaria, Centro Nacional de Microbiología, Majadahonda, Madrid, Spain

^h Servicio de Microbiología, Complejo Hospitalario Universitario A Coruña-INIBIC, A Coruña, Spain

ⁱ Servei de Microbiologia, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

^j Servicio de Microbiología, Hospital Son Espases, Palma de Mallorca, Spain

ARTICLE INFO

Article history:

Received 29 March 2016

Accepted 23 May 2016

Available online 12 September 2017

Keywords:

Quinolone resistance mechanisms

Carbapenemases

Acquired AmpC β-lactamases

ABSTRACT

Background: Quinolone resistance in *Enterobacteriaceae* species has increased over the past few years, and is significantly associated to beta-lactam resistance. The aim of this study was to evaluate the prevalence of chromosomal- and plasmid-mediated quinolone resistance in acquired AmpC β-lactamase and/or carbapenemase-producing *Enterobacteriaceae* isolates.

Methods: The presence of chromosomal- and plasmid-mediated quinolone resistance mechanisms [mutations in the quinolone resistance determining region (QRDR) of *gyrA* and *parC* and *qnr*, *aac(6')-Ib-cr* and *qepA* genes] was evaluated in 289 isolates of acquired AmpC β-lactamase- and/or carbapenemase-producing *Enterobacteriaceae* collected between February and July 2009 in 35 Spanish hospitals.

Results: Plasmid mediated quinolone resistance (PMQR) genes were detected in 92 isolates (31.8%), *qnr* genes were detected in 83 isolates (28.7%), and the *aac(6')-Ib-cr* gene was detected in 20 isolates (7%). *qnrB4* gene was the most prevalent *qnr* gene detected (20%), associated, in most cases, with DHA-1. Only 14.6% of isolates showed no mutations in *gyrA* or *parC* with a ciprofloxacin MIC of 0.5 mg/l or higher, whereas PMQR genes were detected in 90% of such isolates.

Conclusion: *qnrB4* gene was the most prevalent PMQR gene detected, and was significantly associated with acquired AmpC β-lactamase DHA-1. PMQR determinants in association with other chromosomal-mediated quinolone resistance mechanisms, different to mutations in *gyrA* and *parC* (increased energy-dependent efflux, altered lipopolysaccharide or porin loss), could lead to ciprofloxacin MIC values that exceed breakpoints established by the main international committees to define clinical antimicrobial susceptibility breakpoints.

© 2016 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

DOI of original article: <http://dx.doi.org/10.1016/j.eimc.2016.05.006>

[☆] Please cite this article as: Machuca J, Agüero J, Miró E, Conejo MC, Oteo J, Bou G, et al. Prevalencia en España de mecanismos de resistencia a quinolonas en enterobacterias productoras de betalactamasas de clase C adquiridas y/o carbapenemasas. Enferm Infect Microbiol Clin. 2017;35:485–490.

* Corresponding author.

E-mail address: jesmacbar@hotmail.com (J. Machuca).

Prevalencia en España de mecanismos de resistencia a quinolonas en enterobacterias productoras de betalactamasas de clase C adquiridas y/o carbapenemasas

RESUMEN

Palabras clave:

Mecanismos de resistencia a quinolonas
Carbapenemasas
Betalactamasas de clase C adquiridas

Introducción: En los últimos años se ha observado un incremento de la resistencia a fluoroquinolonas en enterobacterias, estando asociado significativamente a la resistencia a betalactámicos. Nuestro objetivo fue conocer la prevalencia de mecanismos cromosómicos y plasmídicos de resistencia a quinolonas en aislados productores de betalactamasas de clase C adquiridas y/o carbapenemasas.

Métodos: Se evaluó la presencia de mecanismos cromosómicos y plasmídicos de resistencia a quinolonas [mutaciones en la región determinante de resistencia a quinolonas de *gyrA* y *parC* y genes *qnr*, *aac(6')-Ib-cr* y *qepA*] en 289 aislados de enterobacterias productoras de betalactamasas de clase C adquiridas y/o carbapenemasas recogidos entre febrero y julio de 2009 en 35 hospitales españoles.

Resultados: Se detectaron determinantes plasmídicos en 92 aislados (31,8%); en 83 aislados (28,7%) se detectó algún gen *qnr*, y en 20 (7%), la variante *aac(6')-Ib-cr*. El gen *qnr* más prevalente fue *qnrB4* (20%), asociado en la mayoría de los casos a DHA-1. El 14,6% de los aislados con una CMI de ciprofloxacinio superior a 0,25 mg/l no presentaban mutaciones en *gyrA* ni *parC*, detectándose en el 90% de los mismos algún determinante plasmídico de resistencia a quinolonas.

Conclusión: *qnrB4* fue el determinante plasmídico más prevalente, claramente asociado a DHA-1. Los mecanismos plasmídicos en asociación con mecanismos cromosómicos diferentes a las mutaciones en los genes de las topoisomerasas (sobreexpresión de bombas de expulsión, alteración del lipopolisacárido o disminución de porinas) pueden dar lugar a valores de CMI de ciprofloxacinio que superan los puntos de corte establecidos por los principales comités internacionales de definición de puntos de corte para interpretación de datos de sensibilidad.

© 2016 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.
Todos los derechos reservados.

Introduction

Fluoroquinolones are broad-spectrum antimicrobials that are used very frequently in clinical practice. For years, high rates of resistance to these antimicrobials have been observed in *Enterobacteriaceae* worldwide.¹ The targets of these compounds are topoisomerase II (or DNA gyrase), and topoisomerase IV. Resistance to quinolones in enterobacteria may be due to multiple causes that are frequently expressed in the same micro-organism. Traditionally, special attention has been paid to mutations that occur in the *gyrA* and *parC* genes encoding subunit A of DNA gyrase and subunit A of topoisomerase IV, respectively; mutations in the *gyrB* and *parE* genes, that encode subunits B of the aforementioned enzymes, are less relevant in clinical isolates. In these genes, the mutations associated with quinolone resistance are located in a concrete region thereof called "quinolone resistance-determining region" (QRDR). In gram-negative bacteria, the primary target of quinolones is DNA gyrase, with the mutations first appearing in *gyrA* and later in *parC*.¹ Despite this, ciprofloxacin-resistant isolates with mutations in *parC* that are not accompanied by *gyrA* mutations² have been reported. A single mutation in *gyrA* causes resistance to nalidixic acid, but confers a low-level resistance (without exceeding the clinical cut-off point) to ciprofloxacin and levofloxacin.³ By increasing the number of mutations in *gyrA* and *parC*, the resistance level also increases until it exceeds the clinical resistance value. Although to a lesser extent, the loss or structural change in the porins, the overexpression of active efflux pumps and changes to lipopolysaccharides also contribute to quinolone resistance.⁴

To date, 3 types of plasmid-mediated quinolone resistance (PMQR) have been reported: *qnr* genes, which encode pentapeptide repeat proteins; the variant in one acetyltransferase, AAC(6')-Ib-cr, which affects piperazinyl group quinolones (for example, ciprofloxacin and norfloxacin), and active OqxAB efflux pump (very common in the *Klebsiella pneumoniae* chromosome) and QepA.⁵ In the past 2 decades, a global increase in the prevalence of PMQR has been observed.⁴

Quinolone resistance is more common in *Enterobacteriaceae* that are beta-lactam resistant, due to production of

extended-spectrum beta-lactamase (ESBL), acquired class C beta-lactamases, or carbapenemases.⁶ In fact, the first description of a *qnr* (*qnrA1*) gene took place in a FOX-5 cephalosporin-producing *K. pneumoniae* strain.⁷ Since then, multiple studies have shown the frequent association between genes encoding the aforementioned beta-lactamases, and different variants of genes encoding PMQR, for example, the case of *qnrA* and *qnrB* with ESBL from the CTX-M group.^{4,8}

This study analyses the presence of chromosomal mutations (in *gyrA* and *parC*) and of PMQRs *qnrA*, *qnrB*, *qnrC*, *qnrD*, *qnrS*, *qepA* and *aac(6')-Ib-cr* in acquired class C beta-lactamase-producing and/or carbapenemase-producing *Enterobacteriaceae* from clinical samples, isolated in a multicentre study with the participation of 35 Spanish hospitals that took place between February and July 2009.⁹ The objective is to study the association between quinolone resistance mechanisms (chromosomal and plasmid-mediated) with acquired class C beta-lactamases and/or carbapenemases in *Enterobacteriaceae*, as well as to determine the prevalence of PMQR in this bacterial population.

Methods

Bacterial isolates

A collection of 289 isolates from acquired class C beta-lactamase-producing and/or carbapenemase-producing *Enterobacteriaceae*, including *Escherichia coli* (n = 163), *K. pneumoniae* (n = 57), *Proteus mirabilis* (n = 45), *Klebsiella oxytoca* (n = 10), *Enterobacter cloacae* (n = 9), *Citrobacter koseri* (n = 3), *Proteus penneri* (n = 1) and *Salmonella* sp. (n = 1) was analysed. Only one isolate per patient was included. The clinical and epidemiological data from this collection were previously described.^{9,10}

Antimicrobial susceptibility and study of quinolone resistance mechanisms

Susceptibility to nalidixic acid and ciprofloxacin was determined using standardised disc diffusion methods and broth

Table 1

Plasmid-mediated quinolone resistance detected by bacterial species.

	<i>E. coli</i> (163)	<i>K. pneumoniae</i> (57)	<i>P. mirabilis</i> (45)	<i>K. oxytoca</i> (10)	<i>E. cloacae</i> (9)	<i>C. koseri</i> (3)	<i>Salmonella</i> sp. (1)	<i>P. penneri</i> (1)
<i>qnrA1</i>	0	1	0	0	1	0	0	0
<i>qnrB4</i>	21 ^a	26 ^a	3	3 ^a	2	2	1	0
<i>qnrB19</i>	0	1	0	0	0	0	0	0
<i>qnrD</i>	0	0	10	0	0	0	0	0
<i>qnrS1</i>	3 ^a	4 ^a	0	0	1	0	0	0
<i>qnrS2</i>	2 ^a	1 ^a	0	4 ^a	1 ^a	0	0	0
<i>aac(6')-lb-cr</i>	9 ^a	7 ^a	0	3 ^a	1 ^a	0	0	0

^a Includes isolates in which 2 different PMQRs were detected (*E. coli*: 1 *qnrB4*+*qnrS1* and 2 *qnrS2*+*aac(6')-lb-cr*; *K. pneumoniae*: 2 *qnrB4*+*qnrS1*, 5 *qnrB4*+*aac(6')-lb-cr* and 1 *qnrS2*+*aac(6')-lb-cr*; *K. oxytoca*: 1 *qnrB4*+*qnrS2* and 2 *qnrS2*+*aac(6')-lb-cr*; *E. cloacae*: 1 *qnrS2*+*aac(6')-lb-cr*).

Table 2

Plasmid-mediated quinolone resistance detected based on the acquired class C beta-lactamase and carbapenemase produced.

	DHA-1 (62)	DHA-7 (1)	CMY-2 (175)	CMY-7 (1)	CMY-27 (2)	AAC-1 (8)	FOX-3 (2)	VIM-1 (25)
<i>qnrA1</i>	0	0	0	0	0	0	0	2
<i>qnrB4</i>	57 ^a	0	1 ^a	0	0	0	0	2 ^a
<i>qnrB19</i>	0	0	0	0	0	0	0	1
<i>qnrD</i>	0	0	10	0	0	0	0	1
<i>qnrS1</i>	3 ^a	0	0	0	1	3	0	1
<i>qnrS2</i>	2 ^a	0	0	0	0	1 ^a	1 ^a	5 ^a
<i>aac(6')-lb-cr</i>	6 ^a	0	7 ^a	1	0	2 ^a	1 ^a	5 ^a

No isolates producing acquired class C beta-lactamases DHA-6, FOX-8, CMY-4, CMY-48, CMY-55, CMY-57, CMY-59 and CMY-60 and carbapenemases IMP-22 and IMP-28 are included because PMQR was not detected in any of them.

^a Includes isolates in which 2 different PMQRs were detected (DHA-1: 3 *qnrB4*+*qnrS1*, 1 *qnrB4*+*qnrS1*, 5 *qnrB4*+*aac(6')-lb-cr* and 1 *qnrS2*+*aac(6')-lb-cr*; CMY-2: 1 *qnrB4*+*aac(6')-lb-cr*; AAC-1: 1 *qnrS2*+*aac(6')-lb-cr*; FOX-3: 1 *qnrS2*+*aac(6')-lb-cr*; VIM-1: 1 *qnrB4*+*aac(6')-lb-cr* and 4 *qnrS2*+*aac(6')-lb-cr*).

microdilution methods, respectively.¹¹ In nalidixic acid-resistant strains (zone of inhibition diameter ≤ 13 mm)¹¹ or with an MIC for ciprofloxacin of ≥ 0.25 mg/l the mutations in the QRDR of *gyrA* were analysed using the previously described methodology.¹² In strains in which no *gyrA* mutations were detected, the presence of *parC* mutations was also studied.¹²

The presence of *qnrA*, *qnrB*, *qnrC*, *qnrD*, *qnrS*, *qepA* and *aac(6')-lb* genes were analysed in all strains using PCR with the previously-described primers.¹³ The amplification products were later sequenced.

Results

PMQR was detected in 92 (31.8%) of the 289 isolates of *Enterobacteriaceae* analysed using PCR and sequencing. The plasmid-mediated quinolone resistance genes detected included 2 *qnrA1*, 59 *qnrB* (58 *qnrB4*, 1 *qnrB19*), 10 *qnrD*, 16 *qnrS* (8 *qnrS1*, 8 *qnrS2*) and 20 *aac(6')-lb-cr*. No *qnrC* or *qepA* determinants were detected in any isolate. Seventy-seven isolates (83.7%) presented a single PMQR. The 15 remaining isolates (16.3%) presented two PMQRs: 6 *aac(6')-lb-cr*+*qnrS2*, 5 *aac(6')-lb-cr*+*qnrB4*, 3 *qnrB4*+*qnrS1* and 1 *qnrB4*+*qnrS2*.

Significant differences were observed in the PMQR type depending on the *Enterobacteriaceae* species (Table 1). Of the 163 *E. coli* isolates, at least one plasmid-mediated determinant was detected in 32 isolates (19.6%). The detected determinants were: 21 *qnrB4*, 5 *qnrS* and 9 *aac(6')-lb-cr*, carrying 3 two PMQR isolates (2 *qnrS2*+*aac(6')-lb-cr* and 1 *qnrB4*+*qnrS1*). Among the *K. pneumoniae* isolates, plasmid-mediated mechanisms were detected in 32 (56.1%). A single plasmid-mediated mechanism was detected in 24, and in 8 there were two detected (2 *qnrB4*+*qnrS1*, 5 *qnrB4*+*aac(6')-lb-cr* and 1 *qnrS2*+*aac(6')-lb-cr*). The PMQR prevalence in the remaining species was: *P. mirabilis* 28.9%, *K. oxytoca* 70%, *E. cloacae* 55.6%, *C. koseri* 66.7%, *Salmonella* sp. 100% and *P. penneri* 0%. The different PMQRs detected in these species are detailed in Table 1. The *qnrD* gene was only detected in *P. mirabilis*. The *qnrS2* determinant was detected in the presence of another plasmid gene in 7 of the 8 isolates that carried it (87.5%).

Among carbapenemase-producing isolates (2 IMP-22 producers, one IMP-28 producer and 25 VIM-1 producers) the PMQR prevalence was 39%, detecting some PMQR in 11 isolates of VIM-1 producers: 2 *qnrA1*, 1 *qnrB19*, 1 *qnrD*, 1 *qnrS1*, 1 *qnrS2*, 1 *qnrB4*+*aac(6')-lb-cr* and 4 *qnrS2*+*aac(6')-lb-cr*.

The prevalence of plasmid-mediated quinolone resistance mechanisms among the 264 acquired class C beta-lactamase-producing isolates was 31.4% (83 isolates). No plasmid-mediated determinants were detected in acquired class C beta-lactamase-producing isolates DHA-6, FOX-8, CMY-4, CMY-48, CMY-55, CMY-57, CMY-59 and CMY-60. The *qnrA1* and *qnrB19* genes were not detected in acquired class C beta-lactamase-producing isolates. The association between PMQR and acquired class C beta-lactamase is shown in Table 2. The predominant class C beta-lactamase in the collection was CMY-2 (175 isolates), detected in 9.7% of the isolates carrying a PMQR in this enzyme. The 10 *qnrD* genes were detected in CMY-2-producing *P. mirabilis* strains. Among the CMY-2-producing *Enterobacteriaceae*, 7 were detected with *aac(6')-lb-cr*.

Among the 62 DHA-1-producing isolates, PMQR was detected in 58 (93.5%), with *qnrB4* being the most frequently found, present in 57 of said isolates (in 9 isolates, a second plasmid-mediated determinant was also detected). The association between *qnrB4* and DHA-1 was statistically significant ($p < 0.05$).

With respect to the chromosomal mechanisms of quinolone resistance, the QRDR of *gyrA* of the nalidixic acid-resistant isolates,¹¹ or that had an MIC for ciprofloxacin equal to or greater than 0.25 mg/l, was analysed. No isolate was found with mutations in *parC*s without also having it in *gyrA*. In *E. coli*, it was verified that all nalidixic acid-resistant isolates showed mutations in the analysed region (Table 3). In this bacterial species there were 4 isolates with MIC for ciprofloxacin of 0.25 mg/l that did not present mutations in *gyrA* or in *parC*; 3 of them presented PMQR. Also, in this *Enterobacteriaceae*, isolates were found with mutations in *gyrA* and PMQR independent of their ciprofloxacin MIC value, something not observed in the isolates from other species, in which only the combination of PMQR and *gyrA* mutations in isolates with ciprofloxacin MICs exceeding 2 mg/l were detected.

Among the isolates of species other than *E. coli*, 9.5% were found to be resistant to nalidixic acid and did not have mutations in the

Table 3

Characteristics of the isolates in the collection by ciprofloxacin MIC.

	MIC of ciprofloxacin (mg/l)					
	≤0.12	0.25	0.5	1	2	>2
<i>E. coli</i> (163)						
Total	28	22	8	3	2	100
Nal R	0	18	8	3	2	100
PMQR	1	3	0	3	1	24
GyrA	ND	18	8	3	2	100
<i>K. pneumoniae</i> (57)						
Total	9	3	8	9	5	23
Nal R	0	0	4	1	3	21
PMQR	1	1	4	8	3	15
GyrA	ND	0	2	0	2	20
<i>P. mirabilis</i> (45)						
Total	11	0	1	3	10	20
Nal R	0	0	0	3	10	20
PMQR	1	0	1	0	0	11
GyrA	ND	0	0	3	1	20
<i>K. oxytoca</i> (10)						
Total	1	0	0	4	2	3
Nal R	0	0	0	0	1	3
PMQR	0	0	0	4	1	2
GyrA	ND	0	0	0	1	3
<i>E. cloacae</i> (9)						
Total	0	1	0	3	2	3
Nal R	0	1	0	1	2	1
PMQR	0	0	0	2	0	3
GyrA	ND	1	0	1	2	1
<i>C. koseri</i> (3)						
Total	1	2	0	0	0	0
Nal R	0	1	0	0	0	0
PMQR	0	2	0	0	0	0
GyrA	ND	0	0	0	0	0
<i>Salmonella</i> spp. (1)						
Total	0	1	0	0	0	0
Nal R	0	1	0	0	0	0
PMQR	0	1	0	0	0	0
GyrA	ND	0	0	0	0	0
<i>P. pemmeri</i> (1)						
Total	0	0	1	0	0	0
Nal R	0	0	1	0	0	0
PMQR	0	0	0	0	0	0
GyrA	ND	0	NA	0	0	0

GyrA, number of isolates with mutations in the QRDR of *gyrA*. No isolate was found without mutations in *gyrA* that had any mutation in *parC*; NA, the QRDR of *gyrA* was not amplified; Nal R, number of isolates resistant to nalidixic acid (halo diameter ≤13 mm); ND, the presence of mutations in *gyrA* in the isolates susceptible to nalidixic acid was not determined (inhibition halo diameter >13 mm)¹¹ or with a ciprofloxacin MIC ≤0.12 mg/l; PMQR, number of isolates of plasmid-mediated quinolone resistance carriers; Total, total number of isolates of each species.

QRDR of *gyrA* or *parC* (Table 3); 66.7% of isolates with a ciprofloxacin MIC equal to or greater than 0.25 mg/l had a mutation in *gyrA* and 52.8% carried some PMQR.

Discussion

The development and expansion of the beta-lactam resistance, linked to the broad-spectrum of fluoroquinolone antimicrobials, led to the use of these drugs as empirical therapy for a wide variety of infections of community and nosocomial origin. The widespread use of quinolones has caused an increase in fluoroquinolone resistance levels worldwide. In Spain, the rate of fluoroquinolone-resistant *E. coli* isolates has increased more than 16% in recent years, going from 17.3% in 2001 to 34% in 2014.¹⁴ The situation of *K. pneumoniae* is similar, with the increased levels of resistance being somewhat lower. In this study, 59% (170) of the acquired class C carbapenemase- or beta-lactamase-carrying isolates analysed were not susceptible to ciprofloxacin. This is a concerning piece of information that highlights the reduced number of therapeutic options for multidrug-resistant *Enterobacteriaceae* isolates.

Fluoroquinolone resistance is mainly due to mutations in the genes of type II topoisomerases and is a sequential process, such that the appearance of the first mutation in *gyrA* favours the appearance of new mutations in *parC* and *gyrA* that entails an increase in the ciprofloxacin MIC above 2 mg/l.¹⁵ The rest of the known resistance mechanisms, both chromosomal and plasmid-mediated mechanisms, confer a low level of resistance that does not exceed the cut-off points established by international agencies.⁵ In the collection analysed in this study, 24 isolates were found (15 *K. pneumoniae*, 5 *K. oxytoca* and 4 *E. cloacae*) with a ciprofloxacin MIC equal to or exceeding 1 mg/l that did not have mutations in the QRDR of either *gyrA* or *parC*; 23 of these isolates present at least one PMQR. The *qnr* genes present in these isolates were *qnrB4* and/or *qnrS* (some isolates also carried the *aac(6')-lb-cr* gene, which are associated with a greater increase in the fluoroquinolone MIC).^{3,16} According to our data, the presence of isolates with an elevated fluoroquinolone MIC in the absence of *gyrA* and *parC* mutations and PMQR carriers has recently been reported in Poland.²

The presence of *qnr* genes favours the appearance of chromosomal mutations that reduce the permeability of fluoroquinolones or increase their expulsion from the cell interior (by means of reducing the number of porins, changes in

lipopolysaccharides or the increase in the expression of efflux pumps), that determines an increase in the ciprofloxacin MIC.^{17,18} Also, the mutations affecting the entry and exit of quinolones appear before the mutations in the QRDRs,¹⁹ something that is consistent with the data obtained in this study, where it is observed that the majority of isolates with a ciprofloxacin MIC between 0.5 and 2 mg/l does not result in the combination of PMQR and chromosomal mutations in the QRDRs. On the other hand, the combination of both mechanisms is observed in strains with MICs above 2 mg/l. Therefore, the high MIC in these isolates could be due to a synergistic combination of PMQRs and chromosomal mutations reducing the intracellular concentration of quinolones, so that in later steps these isolates could acquire mutations in the QRDR of the *gyrA* and *parC* genes, increasing the level of resistance to fluoroquinolones.

One of the current main limitations in the study of the prevalence of PMQRs is the absence of their phenotypic markers,¹³ which leads to the majority of the prevalence information for these resistance genes being conducted in specific populations: fluoroquinolone-resistant isolates or ESBL producers.^{20–22} This makes it difficult to compare studies.

In this study, the prevalence of PMQR in acquired class C beta-lactamase- and/or carbapenemase-producing strains was 32%, a similar value to those found in similar collections.²³ The data regarding carbapenemase-producing strains indicate a PMQR prevalence of 39%, a value less than those found in other regions of the world, such as China, in carbapenem-resistant strains.²⁴ The information obtained from the carbapenemase-producing isolates must be taken with caution due to the low number of beta-lactamase-producing strains included in this study (28). Also, since 2010, an expansion of carbapenemases has taken place in Spain, mainly due to the dispersion of OXA-48, with this enzyme becoming the most prevalent in this country.²⁵ It would therefore be interesting to know about the prevalence of PMQR in beta-lactamase-producing isolates in Spain. In this regard, the coexistence of OXA-48 and AAC(6')-Ib-cr in *K. pneumoniae* has recently been reported in Turkey.²⁶

In our collection, the most prevalent PMQR was *qnrB4* (20%), followed by the *aac(6')-Ib-cr* gene (7%). This data differs from that which is published in many studies where the most prevalent PMQR is *aac(6')-Ib-cr*, followed by *qnrB*.^{21,24,27} This discordance is due to the nature of the collection that is the object of this study, where the high prevalence of *qnrB4* is due to its association with DHA-1,^{28,29} having detected *qnrB4* in 92% of the class C plasmid-mediated beta-lactamase-producing isolates. A previous analysis in 22 of the strains that were considered for this study had already allowed for verification that in the vast majority of *qnrB4* cases the genetic environment of the *bla_{DHA-1}* gene was present.³⁰ Given the different populations analysed in the different studies about the prevalence of PMQR conducted worldwide, it is difficult to compare them. It would be interesting to conduct prevalence studies using unbiased bacterial populations, so that we could obtain prevalence data without over- or underestimates. In this respect, an algorithm was published recently that allowed for phenotypic detection of PMQR in strains lacking QRDR modifications,³¹ which would facilitate the conduct of a study of the prevalence of these resistance mechanisms.

The results obtained support that which is stated by other authors,^{3,16,32} that although the PMQRs to quinolones alone could only cause a moderate level of resistance to quinolones, their association with chromosomal mechanisms could bring the quinolone MIC values above the established cut-off points. Therefore, it would be beneficial to be familiar with the epidemiology of these plasmid-mediating mechanisms and to be able to control their dispersion, given that they could help reduce or prevent increased resistance to quinolones.

Funding

This study was partially funded by the Ministerio de Sanidad, Servicios Sociales e Igualdad [Ministry of Health, Social Services and Equality], Instituto de Salud Carlos III-FEDER [Carlos III-FEDER Health Institute], Red Española de Investigación en Patología Infectiosa [Spanish Network of Infectious Disease Research] (REIPI RD06/0008), via subsidies from the Fondo de Investigación Sanitaria [Health Research Fund] (PS09/00125 and PI11/01117) and assistance from AstraZeneca Farmacéutica España and Wyeth (now Pfizer).

Conflicts of interest

The authors declare that they have no conflicts of interest.

Acknowledgements

To the members of the SEIMC [Spanish Society of Infectious Diseases and Clinical Microbiology] GEMARA and GEIH groups.

References

- Drlica K, Hiasa H, Kerns R, Malik M, Mustae A, Zhao X. Quinolones: action and resistance updated. *Curr Top Med Chem*. 2009;9:981–98.
- Piekarska K, Wolkowicz T, Zacharczuk K, Rzeczkowska M, Chróst A, Bareja E, et al. Co-existence of plasmid-mediated quinolone resistance determinants and mutations in *gyrA* and *parC* among fluoroquinolone-resistant clinical *Enterobacteriaceae* isolated in a tertiary hospital in Warsaw, Poland. *Int J Antimicrob Agents*. 2015;45:238–43.
- Machuca J, Briales A, Labrador G, Díaz-de-Alba P, López-Rojas R, Docobo-Pérez F, et al. Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in *Escherichia coli*. *J Antimicrob Chemother*. 2014;69:3203–15.
- Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone resistance: a multifaceted threat. *Clin Microbiol Rev*. 2009;22:664–89.
- Jacoby GA, Strahilevitz J, Hooper DC. Plasmid-mediated quinolone resistance. *Microbiol Spectr*. 2014;2.
- Tolun V, Küçükbaşmaci O, Törümküney-Akulut D, Catal C, Anğ-Küçüker M, Anğ O. Relationship between ciprofloxacin resistance and extended-spectrum beta-lactamase production in *Escherichia coli* and *Klebsiella pneumoniae* strains. *Clin Microbiol Infect*. 2004;10:72–5.
- Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. *Lancet*. 1998;351:797–9.
- Corkill JE, Anson JJ, Hart CA. High prevalence of the plasmid-mediated quinolone resistance determinant *qnrA* in multidrug-resistant *Enterobacteriaceae* from blood cultures in Liverpool, UK. *J Antimicrob Chemother*. 2005;56:1115–7.
- Miró E, Agtiero J, Larrosa MN, Fernández A, Conejo MC, Bou G, et al. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in *Enterobacteriaceae* isolates from 35 hospitals in Spain. *Eur J Clin Microbiol Infect Dis*. 2013;32:253–9.
- Rodríguez-Baño J, Miró E, Villar M, Coelho A, Gozalo M, Borrell N, et al. Colonisation and infection due to *Enterobacteriaceae* producing plasmid-mediated AmpC β-lactamases. *J Infect*. 2012;64:176–83.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Twenty-fourth informational supplement M100-S25. Wayne, PA, USA: CLSI; 2015.
- Rodríguez-Martínez JM, Velasco C, Pascual A, García I, Martínez-Martínez L. Correlation of quinolone resistance levels and differences in basal and quinolone-induced expression from three *qnrA*-containing plasmids. *Clin Microbiol Infect*. 2006;12:440–5.
- Rodríguez-Martínez JM, Cano ME, Velasco C, Martínez-Martínez L, Pascual A. Plasmid-mediated quinolone resistance: an update. *J Infect Chemother*. 2011;17:149–82.
- European Centre for Disease Prevention and Control. European Antimicrobial Resistance Surveillance Network (EARS-Net). Available from: <http://ecdc.europa.eu> [accessed 16.05.16].
- Bansal S, Tandon V. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in *Escherichia coli* clinical isolates. *Int J Antimicrob Agents*. 2011;37:253–5.
- Briales A, Rodríguez-Martínez JM, Velasco C, Díaz de Alba P, Domínguez-Herrera J, Pachón J, et al. In vitro effect of *qnrA1*, *qnrB1*, and *qnrS1* genes on fluoroquinolone activity against isogenic *Escherichia coli* isolates with mutations in *gyrA* and *parC*. *Antimicrob Agents Chemother*. 2011;55:1266–9.
- Cesaro A, Bettoni RRD, Lascols C, Mérens A, Soussy CJ, Cambau E. Low selection of topoisomerase mutants from strains of *Escherichia coli* harbouring plasmid-borne *qnr* genes. *J Antimicrob Chemother*. 2008;61:1007–15.

18. Vinué L, Corcoran MA, Hooper DC, Jacoby GA. Mutations that enhance the ciprofloxacin resistance of *Escherichia coli* with *qnrA1*. *Antimicrob Agents Chemother.* 2015;60:1537–45.
19. Singh R, Swick MC, Ledesma KR, Yang Z, Hu M, Zechiedrich L, et al. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in *Escherichia coli*. *Antimicrob Agents Chemother.* 2012;56:1680–5.
20. Yang HY, Nam YS, Lee HJ. Prevalence of plasmid-mediated quinolone resistance genes among ciprofloxacin-nonsusceptible *Escherichia coli* and *Klebsiella pneumoniae* isolated from blood cultures in Korea. *Can J Infect Dis Med Microbiol.* 2014;25:163–9.
21. Briales A, Rodríguez-Martínez JM, Velasco C, de Alba PD, Rodríguez-Baño J, Martínez-Martínez L, et al. Prevalence of plasmid-mediated quinolone resistance determinants *qnr* and *aac(6')-Ib-cr* in *Escherichia coli* and *Klebsiella pneumoniae* producing extended-spectrum β-lactamases in Spain. *Int J Antimicrob Agents.* 2012;39:431–4.
22. Shams E, Firoozeh F, Moniri R, Zibaei M. Prevalence of plasmid-mediated quinolone resistance genes among extended-spectrum β-lactamase-producing *Klebsiella pneumoniae* human isolates in Iran. *J Pathog.* 2015;2015:434391.
23. Alonso N, Miró E, Pascual V, Rivera A, Simó M, García MC, et al. Molecular characterisation of acquired and overproduced chromosomal *bla_{AmpC}* in *Escherichia coli* clinical isolates. *Int J Antimicrob Agents.* 2016;47:62–8.
24. Jiang Y, Zhou Z, Qian Y, Wei Z, Yu Y, Hu S, et al. Plasmid-mediated quinolone resistance determinants *qnr* and *aac(6')-Ib-cr* in extended-spectrum β-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in China. *J Antimicrob Chemother.* 2008;61:1003–6.
25. Oteo J, Ortega A, Bartolomé R, Bou G, Conejo C, Fernández-Martínez M, et al. Prospective multicenter study of carbapenemase-producing *Enterobacteriaceae* from 83 Hospitals in Spain reveals high *in vitro* susceptibility to colistin and meropenem. *Antimicrob Agents Chemother.* 2015;59:3406–12.
26. Nazik H, Öngen B, Mete B, Aydin S, Yemişen M, Keleşoğlu FM, et al. Coexistence of *bla_{OXA-48}* and *aac(6')-Ib-cr* genes in *Klebsiella pneumoniae* isolates from Istanbul, Turkey. *J Int Med Res.* 2011;39:1932–40.
27. Karah N, Poirel L, Bengtsson S, Sundqvist M, Kahlmeter G, Nordmann P, et al. Plasmid-mediated quinolone resistance determinants *qnr* and *aac(6')-Ib-cr* in *Escherichia coli* and *Klebsiella* spp. from Norway and Sweden. *Diagn Microbiol Infect Dis.* 2010;66:425–31.
28. Mata C, Miró E, Tolera M, Rivera MA, Walsh TR, Navarro F. Association of *bla_{DHA-1}* and *qnrB* genes carried by broad-host-range plasmids among isolates of *Enterobacteriaceae* at a Spanish hospital. *Clin Microbiol Infect.* 2011;17:1514–7.
29. Pai H, Seo M-R, Choi TY. Association of *QnrB* determinants and production of extended-spectrum beta-lactamases or plasmid-mediated *AmpC* beta-lactamases in clinical isolates of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2007;51:366–8.
30. Zamorano L, Miró E, Juan C, Gómez L, Bou G, González-López JJ, et al. Mobile genetic elements related to the diffusion of plasmid-mediated *AmpC* β-lactamases or carbapenemases from *Enterobacteriaceae*: findings from a multicenter study in Spain. *Antimicrob Agents Chemother.* 2015;59:5260–6.
31. Rodríguez-Martínez J-M, López-Cerero L, Díaz-de-Alba P, Chamizo-López FJ, Polo-Padillo J, Pascual A. Assessment of a phenotypic algorithm to detect plasmid-mediated quinolone resistance in *Enterobacteriaceae*. *J Antimicrob Chemother.* 2016;71:845–7.
32. Machuca J, Briales A, Díaz-de-Alba P, Martínez-Martínez L, Pascual A, Rodríguez-Martínez J-M. Effect of the efflux pump *QepA2* combined with chromosomally mediated mechanisms on quinolone resistance and bacterial fitness in *Escherichia coli*. *J Antimicrob Chemother.* 2015;70:2524–7.